Literature DB >> 10811262

Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus.

D D Addie1, J M Dennis, S Toth, J J Callanan, S Reid, O Jarrett.   

Abstract

A closed household of 26 cats in which feline coronavirus (FCoV), feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV) were endemic was observed for 10 years. Each cat was seropositive for FCoV on at least one occasion and the infection was maintained by reinfection. After 10 years, three of six surviving cats were still seropositive. Only one cat, which was also infected with FIV, developed feline infectious peritonitis (FIP). Rising anti-FCoV antibody titres did not indicate that the cat would develop FIP. The FeLV infection was self-limiting because all seven of the initially viraemic cats died within five years and the remainder were immune. However, FeLV had the greatest impact on mortality. Nine cats were initially FIV-positive and six more cats became infected during the course of the study, without evidence of having been bitten. The FIV infection did not adversely affect the cats' life expectancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811262     DOI: 10.1136/vr.146.15.419

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  23 in total

1.  Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western Canada: Prevalence, disease associations, and survival analysis.

Authors:  Madhu Ravi; Gary A Wobeser; Susan M Taylor; Marion L Jackson
Journal:  Can Vet J       Date:  2010-03       Impact factor: 1.008

2.  A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Authors:  Géraldine Schlecht-Louf; Marianne Mangeney; Hanane El-Garch; Valérie Lacombe; Hervé Poulet; Thierry Heidmann
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

3.  Contrasting clinical outcomes in two cohorts of cats naturally infected with feline immunodeficiency virus (FIV).

Authors:  Paweł M Bęczkowski; Annette Litster; Tsang Long Lin; Dominic J Mellor; Brian J Willett; Margaret J Hosie
Journal:  Vet Microbiol       Date:  2015-01-03       Impact factor: 3.293

4.  Comparison of risk factors for seropositivity to feline immunodeficiency virus and feline leukemia virus among cats: a case-case study.

Authors:  Bimal K Chhetri; Olaf Berke; David L Pearl; Dorothee Bienzle
Journal:  BMC Vet Res       Date:  2015-02-10       Impact factor: 2.741

5.  Feline immunodeficiency virus in puma: Estimation of force of infection reveals insights into transmission.

Authors:  Jennifer J H Reynolds; Scott Carver; Mark W Cunningham; Ken A Logan; Winston Vickers; Kevin R Crooks; Sue VandeWoude; Meggan E Craft
Journal:  Ecol Evol       Date:  2019-09-26       Impact factor: 2.912

Review 6.  Feline coronavirus in multicat environments.

Authors:  Yvonne Drechsler; Ana Alcaraz; Frank J Bossong; Ellen W Collisson; Pedro Paulo V P Diniz
Journal:  Vet Clin North Am Small Anim Pract       Date:  2011-11       Impact factor: 2.093

Review 7.  Clinical aspects of feline retroviruses: a review.

Authors:  Katrin Hartmann
Journal:  Viruses       Date:  2012-10-31       Impact factor: 5.048

8.  MERS coronavirus in dromedary camel herd, Saudi Arabia.

Authors:  Maged G Hemida; Daniel K W Chu; Leo L M Poon; Ranawaka A P M Perera; Mohammad A Alhammadi; Hoi-Yee Ng; Lewis Y Siu; Yi Guan; Abdelmohsen Alnaeem; Malik Peiris
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

Review 9.  Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.

Authors:  Katrin Hartmann; Anita Wooding; Michèle Bergmann
Journal:  Vet Sci       Date:  2015-12-18

10.  Epidemiology and clinical outcomes of feline immunodeficiency virus and feline leukaemia virus in client-owned cats in New Zealand.

Authors:  Claire Luckman; M Carolyn Gates
Journal:  JFMS Open Rep       Date:  2017-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.